Who are Permitted DMARDs's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Leflunomide 10 milligram (MG), Methotrexate plus sulfasalazine, Leflunomide plus Methotrexate, Placebo (PLA) + MTX, DB, Methotrexate, Hydroxychloroquine, Leflunomide-Sulfasalazine-Hydroxychloroquine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/permitted-dmards.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Permitted DMARDs — Competitive Intelligence Brief

Permitted DMARDs (Permitted DMARDs) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Disease-Modifying Antirheumatic Drug (DMARD). Area: Immunology / Rheumatology.

phase 3 Disease-Modifying Antirheumatic Drug (DMARD) Immunology / Rheumatology Small molecule Live · refreshed every 30 min

Target snapshot

Permitted DMARDs (Permitted DMARDs) — Hoffmann-La Roche. DMARDs (Disease-Modifying Antirheumatic Drugs) suppress immune system activity to reduce inflammation and slow progression of autoimmune diseases.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Permitted DMARDs TARGET	Permitted DMARDs	Hoffmann-La Roche	phase 3	Disease-Modifying Antirheumatic Drug (DMARD)
Leflunomide 10 milligram (MG)	Leflunomide 10 milligram (MG)	P. Verschueren	marketed	DHODH inhibitor; disease-modifying antirheumatic drug (DMARD)	Dihydroorotate dehydrogenase (DHODH)
Methotrexate plus sulfasalazine	Methotrexate plus sulfasalazine	Singapore General Hospital	marketed	Disease-modifying antirheumatic drug (DMARD) combination	Multiple (dihydrofolate reductase, folate metabolism; sulfapyridine and 5-ASA mechanisms)
Leflunomide plus Methotrexate	Leflunomide plus Methotrexate	Bangladesh Medical University	marketed	Disease-modifying antirheumatic drug (DMARD) combination	Dihydroorotate dehydrogenase (leflunomide); Dihydrofolate reductase (methotrexate)
Placebo (PLA) + MTX, DB	Placebo (PLA) + MTX, DB	Bristol-Myers Squibb	phase 3	Disease-modifying antirheumatic drug (DMARD)	Dihydrofolate reductase (DHFR)
Methotrexate, Hydroxychloroquine	Methotrexate, Hydroxychloroquine	Sanjay Gandhi Postgraduate Institute of Medical Sciences	phase 3	Immunosuppressive/Disease-modifying antirheumatic drug (DMARD) combination	Dihydrofolate reductase (methotrexate); Toll-like receptors and lysosomal pH (hydroxychloroquine)
Leflunomide-Sulfasalazine-Hydroxychloroquine	Leflunomide-Sulfasalazine-Hydroxychloroquine	University of Nebraska	phase 3	Disease-modifying antirheumatic drug (DMARD) combination	Multiple targets: dihydroorotate dehydrogenase (leflunomide), NF-κB pathway (sulfasalazine), lysosomal function and TLR signaling (hydroxychloroquine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Disease-Modifying Antirheumatic Drug (DMARD) class)

Hoffmann-La Roche · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Permitted DMARDs — Competitive Intelligence Brief. https://druglandscape.com/ci/permitted-dmards. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab